OMER - Omeros: Multibagger On The Horizon

• Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021.
• This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare, unmet, life-threatening disease.
• FDA signals it could be an easy approval of the potential blockbuster drug.
• Narsoplimab is a platform for multiple indications. The upcoming first approval would validate the science behind it and would unlock the remaining value of the pipeline.
• Scientific evidence indicates that narsoplimab is superior to the competition.

For further details see: